Sobi spotlights olezarsen pancreatitis data at EAS 2026

Sobi said a new pooled analysis of its pivotal Phase 3 CORE and CORE2 trials found that olezarsen, marketed as Tryngolza, reduced triglycerides by 66% after six months and cut the relative risk of acute pancreatitis by 85% in adults with severe hypertriglyceridemia, defined in this analysis as baseline triglycerides of at least 880 mg/dL. The company presented the data as a late-breaking abstract at the European Atherosclerosis Society Congress 2026 in Athens. The analysis focused on 455 patients from the broader CORE and CORE2 studies, which previously supported regulatory filings in the U.S. and Europe. (sobi.com)

Why it matters: While this is a human medicine story, it’s relevant to veterinary professionals because it reflects how drug developers and regulators are increasingly emphasizing outcomes beyond biomarker improvement alone. In this case, Sobi is highlighting not just triglyceride lowering, but a reduction in acute pancreatitis risk, a clinically meaningful endpoint in a population with limited treatment options. The data build on results published in The New England Journal of Medicine on January 29, 2026, and come as the European Medicines Agency has already validated an indication extension application and the FDA is reviewing a supplemental application with a June 30, 2026, PDUFA date. (nejm.org)

What to watch: Watch for regulatory decisions in the U.S. and Europe, and for whether clinicians and guideline groups treat pancreatitis reduction as the key differentiator for apoC-III-targeting therapies. (prnewswire.com)